Eli Lilly and Company (LLY)
| Market Cap | 767.88B |
| Revenue (ttm) | 53.26B |
| Net Income (ttm) | 13.80B |
| Shares Out | 897.74M |
| EPS (ttm) | 15.29 |
| PE Ratio | 55.93 |
| Forward PE | 30.89 |
| Dividend | $6.00 (0.70%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 3,071,573 |
| Open | 851.69 |
| Previous Close | 845.72 |
| Day's Range | 845.70 - 860.25 |
| 52-Week Range | 623.78 - 937.00 |
| Beta | 0.46 |
| Analysts | Strong Buy |
| Price Target | 969.56 (+13.35%) |
| Earnings Date | Oct 30, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $969.56, which is an increase of 13.35% from the latest price.
News
A Pricing Powerhouse, Now 30% Cheaper: Is Eli Lilly Stock A Buy?
Eli Lilly (LLY) stock merits your attention. Why? Because it offers monopoly-like high margins at a reduced price.
HealthTap joins Lilly's online platform to offer diabetes management services
Telehealth company HealthTap said on Wednesday it is joining Eli Lilly's digital healthcare platform, LillyDirect, to offer virtual diabetes management services.
Former FDA vaccine chief Peter Marks joins Eli Lilly, STAT reports
Peter Marks, the former top vaccine regulator at the U.S. Food and Drug Administration, has joined Eli Lilly , STAT News reported on Tuesday.
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Approximately 80% of Omvoh-treated patients in the LUCENT-3 study who achieved clinical remission at one year maintained long-term, corticosteroid-free clinical and endoscopic remission At four years,...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
"Exciting Race" Between LLY & NVO, Tariffs Remain Long-Term Overhang
Lee Brown sees lots of potential in the weight loss drug space, noting Eli Lilly (LLY) and Novo Nordisk (NVO) as the two companies he expects to lead. He points to "incredible" discounts and expanded ...
Eli Lilly to invest over $1 billion in India to expand manufacturing capacity
Eli Lilly will invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, as it seeks to tap into skilled workforc...
Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated
Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, e...
Top 50 High-Quality Dividend Growth Stocks For October 2025
I track a universe of 50 high-quality dividend growth stocks to identify opportune investments based on valuation and future return potential. As of October 2, 2025, 22 stocks offer attractive future ...
Kernal Bio Joins Lilly Gateway Labs to Accelerate In Vivo Cell Therapies
BOSTON--(BUSINESS WIRE)-- #AI--Kernal Bio retains strategic independence, while gaining access to shared resources, operational support and Lilly's global network of experts.
Buy LLY Stock At $820?
The entire pharmaceutical sector is experiencing a rerating this week, as investors realize the adverse impact of tariffs and drug price cuts won't be as severe as previously anticipated. While most m...
How I Would Build An Ultra-High-Conviction Retirement Portfolio Right Now
Building a resilient retirement portfolio requires a mix of disruption-proof income from REITs, midstream energy, and high-yielding assets, plus growth stocks and ETFs. Current market challenges—AI di...
Why Eli Lilly Is The Lion's Share Of My Portfolio
Healthcare is underowned; 2026 rate cuts and policy clarity should trigger inflows. As XLV's largest weight and obesity leader, Lilly will capture outsized demand during the sector re-rating cycle. Or...
ABBV Stock vs. Eli Lilly & Merck
AbbVie stock (NYSE: ABBV) rallied 11% in a week, largely driven by a key development that boosted the entire sector: Pfizer's agreement to lower its drug prices for Medicaid and a White House decision...
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
Novo Nordisk's and Eli Lilly's blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity and its complications, a major European medical association advised on Thu...
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
Top Stock Movers Now: Nike, Eli Lilly, Corteva, AES, and More
The S&P 500, Dow, and Nasdaq were little changed Wednesday afternoon, as a federal government shutdown took effect.
Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away
Pfizer Inc's (NYSE:PFE) deal with Washington isn't just a handshake in the Oval Office — it's a seismic jolt to America's drug-pricing game. By agreeing to sell medicines on the government's new Trump...
Drug-Pricing Deals And Discounted Bets: Why LLY Stock Is A Core Pick In Our Top 10
Eli Lilly stock (NYSE: LLY) surged 5% yesterday, initially driven by news of a Pfizer deal with the White House to lower drug prices in exchange for tariff immunity. Following this, reports surfaced t...
Eli Lilly in negotiations with Trump administration for the next pharma deal
CNBC's Eamon Javers reports on news regarding the White House.
Eli Lilly: Strong Buy On Sustained Growth, Expanding Moat, And Pipeline Depth
Eli Lilly's valuation has compressed significantly from last year's highs, despite fundamentals improving faster than its share price. Industry-leading incretin treatments (Mounjaro, Zepbound) are dri...
LLY Stock Set For A 20% Breakout?
Eli Lilly stock (NYSE: LLY) should be on your radar. Here's why – it is presently trading within the support range ($688 – $761), price points from which it has previously bounced significantly.
Novo, Lilly Weight-Loss Drugs May Help Alzheimer's Patients. What It Means for the Stocks.
The blockbuster medications could open a new frontier for the pharma giants.